Researchers call for intensified efforts to help men with prostate cancer quit smoking after a recent MSK study revealed that patients who smoke during radiation therapy face a higher risk of both having the disease return and dying from it.
From tropical plants and 3-D snapshots of worms to tiny particles that light up tumors, here’s a glimpse at some of the fascinating work MSK researchers pursued in 2014 as part of our quest to advance cancer science.
Researchers have created tiny structures called organoids from patients’ prostate tumors. These organoids will allow the study of tumors in greater detail and enable correlation of genetic mutations with drug response.
An earlier post about active surveillance as a management strategy for prostate cancer generated an engaged and meaningful discussion on this blog, especially about the risks of “doing nothing.” Here we take a closer look at the concept of risk.
Dr. Parra, who practices at Memorial Sloan Kettering Basking Ridge, treats prostate, kidney, and bladder cancers with the goal of extending the lives of patients, and giving them the best possible quality of life.
Memorial Sloan Kettering’s prostate cancer team — including Howard I. Scher, Chief of the Genitourinary Oncology Service — disagrees with new PSA screening recommendations released by government task force.
In an extraordinary demonstration of excellence, five Memorial Sloan Kettering physician-scientists were selected to participate in the press program at the 2011 American Society of Clinical Oncology annual meeting, held June 3-7 in Chicago.
Research led by radiation oncologist William Polkinghorn and physician-scientist Charles Sawyers suggests that analyzing a tumor’s DNA may identify prostate cancer patients who would benefit from radiation alone or in combination with other treatments.
Epidemiologist Helena Furberg commented on a study that found that men who are overweight are more likely to have precancerous lesions detected in a benign prostate biopsy and are at a greater risk for subsequently developing prostate cancer.
The final survival analysis of an international study of a new drug for prostate cancer has found an even greater median survival benefit than previously reported, and has established a new class of treatment for men with metastatic prostate cancer. In addition, researchers are exploring a potential biomarker of response to treatment in general.
An international, multi-center study has found that a recently FDA-approved drug called abiraterone acetate significantly improves overall survival in men with metastatic prostate cancer by more than 34 percent. Researchers at Memorial Sloan Kettering Cancer Center, the Institute of Cancer Research and the Royal Marsden Hospital in the UK as well as other cancer centers around the world published the findings in the May 26, 2011, issue of The New England Journal of Medicine.